Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2004; 43:276-283, doi:10.1016/j.jacc.2003.08.040
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kunichika, H.
Right arrow Articles by DeMaria, A. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kunichika, H.
Right arrow Articles by DeMaria, A. N.

Effects of glycoprotein iib/iiia inhibition on microvascular flow after coronary reperfusion

A quantitative myocardial contrast echocardiography study

Hideki Kunichika, MD, PhD*, Ori Ben-Yehuda, MD, FACC*, Stephane Lafitte, MD*, Naomi Kunichika, MD, PhD*, Barry Peters, MD* and Anthony N. DeMaria, MD, MACC*,*

* Division of Cardiology, University of California at San Diego, San Diego, California, USA



View larger version (16K):

[in a new window]
 
Figure 1 Time course of changes in the rate of intensity rise (b) parameter measurements by myocardial contrast echocardiography within the risk area at baseline, occlusion, and after coronary reperfusion for each control (n = 8) and glycoprotein IIb/IIIa inhibitor (GPI) (n = 8) group. *p < 0.05 versus control group at each stage. Data are expressed as the mean ± SD. R-30, R-60, R-90, and R-180 = reperfusion for 30, 60, 90, and 180 min, respectively.

 


View larger version (62K):

[in a new window]
 
Figure 2 Representative end-systolic myocardial contrast echocardiography images by real-time imaging after high-energy fast low-angle shot (FLASH) transmission at 180-min reperfusion in both control and glycoprotein IIb/IIIa inhibitor (GPI) dogs. Arrows show an opacification defect after FLASH images. The defect size in the control group is larger than that in the GPI group.

 


View larger version (16K):

[in a new window]
 
Figure 3 Correlation between the size of the infarct area by triphenyltetrazolium chloride (TTC) and that by myocardial contrast echocardiography (MCE) at 180-min reperfusion (control: n = 4; glycoprotein IIb/IIIa inhibitor [GPI]: n = 4). LV = left ventricle.

 


View larger version (16K):

[in a new window]
 
Figure 4 Time course of changes in the myocardial blood flow within the risk area at baseline, occlusion, and after coronary reperfusion for the control (n = 8) and glycoprotein IIb/IIIa inhibitor (GPI) (n = 8) groups. *p < 0.05 versus control group at each stage. The data during occlusion and reperfusion are expressed as the mean percentage of baseline ± SD. R-30, R-60, R-90, and R-180 = reperfusion for 30, 60, 90, and 180 min, respectively.

 


View larger version (18K):

[in a new window]
 
Figure 5 The relationship between infarct size at risk and mean myocardial blood flow (MBF) of risk area during coronary occlusion is illustrated for the control (n = 8) and glycoprotein IIb/IIIa inhibitor (GPI) (n = 8) groups. Each point represents an individual dog. A significant downward shift in the line of the inverse relationship was observed in the GPI-treated group (p < 0.05).

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement